Trials / Completed
CompletedNCT01180465
A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity
A Multi-center, Randomized, Double-masked, Placebo-controlled, Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Neothetics, Inc · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
LIPO-102 is under evaluation for treatment of abdominal adiposity
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LIPO-102 | LIPO-102 High dose |
| DRUG | LIPO-102 Low | LIPO-102 Low dose |
| DRUG | LIPO-102, Placebo | Placebo |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2010-08-12
- Last updated
- 2015-03-26
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01180465. Inclusion in this directory is not an endorsement.